Randolph Ross, MD
Pulmonary Disease · Hattiesburg, MSNPI 1295267680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,753, more than ten times the $14 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.
Across 268 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$975
- Boehringer Ingelheim$554
- GSK$435
- Sanofi$315
- Regeneron Healthcare Solutions, Inc.$271
- Mylan Specialty L.p.$253
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,040100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $975 |
| Boehringer Ingelheim | 32 | $554 |
| GSK | 32 | $435 |
| Sanofi | 14 | $315 |
| Regeneron Healthcare Solutions, Inc. | 11 | $271 |
| Mylan Specialty L.p. | 14 | $253 |
| Intuitive Surgical | 4 | $225 |
| ANI Pharmaceuticals, Inc. | 4 | $224 |
| Viatris Specialty LLC | 15 | $202 |
| Grifols USA, LLC | 9 | $201 |
| Electromed, Inc. | 20 | $196 |
| Pfizer | 11 | $174 |
| Merck | 8 | $146 |
| Verona Pharma, Inc. | 5 | $109 |
| United Therapeutics Corporation | 5 | $96 |
| Jazz Pharmaceuticals Inc. | 4 | $85 |
| Mallinckrodt Hospital Products Inc. | 3 | $80 |
| Shionogi Inc | 5 | $79 |
| Insmed, Inc. | 5 | $72 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Inari Medical, Inc. | 3 | $45 |
| Baxter Healthcare | 2 | $45 |
| La Jolla Pharmaceutical Company | 2 | $36 |
| Amgen | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Philips North America LLC | 1 | $23 |
| Liquidia Technologies, Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,040 in reported general payments places this provider in the 50th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $105,433 |
| NucalaMepolizumab | 11 | $65,617 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $62,976 |
| Fasenra PenBenralizumab | 11 | $62,444 |
| Advair HfaFluticasone Propion/Salmeterol | 52 | $30,899 |
| Spiriva RespimatTiotropium Bromide | 48 | $28,190 |
| XareltoRivaroxaban | 14 | $16,711 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $13,471 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 382 | $12,749 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $11,022 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $9,335 |
| DuleraMometasone/Formoterol | 20 | $7,171 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,117 |
| Arnuity ElliptaFluticasone Furoate | 17 | $4,670 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $4,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $435 | $182,836179 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $975 | $73,998114 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $554 | $37,52568 claims |
| MerckDulera | $146 | $7,17120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Hattiesburg
- L AldredHattiesburg$76K
- Walid YounisHattiesburg$15K
- Tamer HudaliHattiesburg$15K
- Michael RaggioHattiesburg$11K
- Lewis NeeseHattiesburg$9K
- Kevin KinlochHattiesburg$6K
- Charles McCollumHattiesburg$4K
- Andrew RognessHattiesburg$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.